REFERENCES
- Jones P W. St. George's Respiratory Questionnaire: MCID. J COPD 2005, this issue.
- Brown C D, Wise R A. Minimal clinically important differences in the six minute walk test and the incremental shuttle walking test. J COPD 2005, this issue.
- Schunemann H J, Puhan M, Goldstein R, Jaeschke R, Guyatt G H. Measurement properties and interpretability of the Chronic Respiratory Disease Questionnaire (CRQ). J COPD 2005, this issue.
- Ries A L. Minimally clinically important difference for the UCSD shortness of breath questionnaire, Borg Scale, and Visual Analog Scale. J COPD 2005, this issue.
- Casaburi R. Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. J COPD 2005, this issue.
- ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211–277. [CSA], [CROSSREF]
- Cotes J E. Rating respiratory disability: a report on behalf of a working group of the European society for clinical respiratory physiology. Eur Respir J 1990; 3:1074–1077. [PUBMED], [INFOTRIEVE]
- Cox N M, Hendrik J CM, Binkhorst R A, Folgering H TM, van Herwaarden C L. Reproducibility of incremental maximum cycle ergometer tests in patients with mild to moderate obstructive lung disease. Lung 1989; 167:129–133. [PUBMED], [INFOTRIEVE]
- Rationale and design of the National Emphysema Treatment Trial (NETT): a prospective randomized trial of lung volume reduction surgery. J Thorac Cardiovasc Surg 1999; 118:518–528.
- Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood D E. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059–2073. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001; 345:1075–1083. [CSA], [CROSSREF]
- Norman G R, Sloan J A, Wyrwich K W. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41:582–592. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kazis L E, Anderson J J, Meenan R F. Effect sizes for interpreting changes in health status. Med Care 1989; 27:S178–S189. [PUBMED], [INFOTRIEVE]
- Wyrwich K W, Nienaber N A, Tierney W M, Wolinsky F D. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999; 37:469–478. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wyrwich K W, Tierney W M, Wolinsky F D. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52:861–873. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, Brooks P, Tugwell P. Minimal clinically important differences: review of methods. J Rheumatol 2001; 28:406–412. [PUBMED], [INFOTRIEVE]
- Guyatt G H, Osoba D, Wu A W, Wyrwich K W, Norman G R. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77:371–383. [PUBMED], [INFOTRIEVE], [CSA]
- Cox N J, Hendriks J C, Binkhorst R A, Folgering H T, van Herwaarden C L. Reproducibility of incremental maximum cycle ergometer tests in patients with mild to moderate obstructive lung diseases. Lung 1989; 167:129–133. [PUBMED], [INFOTRIEVE]
- Fabbri L M, Hurd S S. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22:1–2. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Calverley P, Pauwels R A, Vestbo J, Jones P W, Pride N B, Gulsvik A, Anderson J A, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449–456. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Casaburi R, Mahler D, Jones P W, Wanner A, Pedro G S, ZuWallack R L, Menjoge S S, Serby C W. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217–224. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hanania N A, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate/salmeterol combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834–843. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Burge P S, Calverley P MA, Spencer J S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297–1303. [PUBMED], [INFOTRIEVE], [CROSSREF]